[Usefulness of neuron specific enolase in patients with head and neck malignant tumors].

Le résumé fourni par la source

The authors present results of evaluation of neuron specific enolase (NSE) in 146 persons. We analyzed a concentration of NSE in preliminary study and in monitoring depending on clinical advances of tumour, mass of primary tumour and metastases to lymph nodes. Neuron specific enolase was excluded because the number of positive results was the same both in the main and control group. Our results indicate that evaluation of NSE have not height value in monitoring patients with head and neck carcinoma.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.